{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wu D"],"funding":["Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","Physician Growth Plan for Digestive Tract Cancers and Precancers"],"pagination":["7050"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9739995"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(23)"],"pubmed_abstract":["Background: Quadruple therapy with polaprezinc provided an alternative to Helicobacter pylori eradication; however, the effect on gut microbiota remains uncertain. This study aims to identify whether polaprezinc-containing quadruple therapy causes adverse microbiota effects among asymptomatic adults, compared with bismuth therapy. Methods: This was a randomized control trial. One hundred asymptomatic H. pylori-infected adults were randomly (1:1) assigned to two treatment groups (polaprezinc-containing therapy, PQT; or bismuth-containing therapy, BQT). Fecal samples were collected from subjects before and 4−8 weeks after therapy. Samples were sequenced for the V4 regions of the 16S rRNA gene. Results: The relative abundance of the three dominant bacterial phyla (Bacteroidota, Firmicutes, an"],"journal":["Journal of clinical medicine"],"pubmed_title":["The Effect of Quadruple Therapy with Polaprezinc or Bismuth on Gut Microbiota after <i>Helicobacter pylori</i> Eradication: A Randomized Controlled Trial."],"pmcid":["PMC9739995"],"funding_grant_id":["2016-I2M-3-001","GTCZ-2020-SC-51-0010"],"pubmed_authors":["Xie W","Li J","Qin J","Jiang H","Wu D","Sun Z","Zhao Y","Li X","Liu Y","Li T","Chen W","Wu W","Tan Q","Chen T"],"additional_accession":[]},"is_claimable":false,"name":"The Effect of Quadruple Therapy with Polaprezinc or Bismuth on Gut Microbiota after <i>Helicobacter pylori</i> Eradication: A Randomized Controlled Trial.","description":"Background: Quadruple therapy with polaprezinc provided an alternative to Helicobacter pylori eradication; however, the effect on gut microbiota remains uncertain. This study aims to identify whether polaprezinc-containing quadruple therapy causes adverse microbiota effects among asymptomatic adults, compared with bismuth therapy. Methods: This was a randomized control trial. One hundred asymptomatic H. pylori-infected adults were randomly (1:1) assigned to two treatment groups (polaprezinc-containing therapy, PQT; or bismuth-containing therapy, BQT). Fecal samples were collected from subjects before and 4−8 weeks after therapy. Samples were sequenced for the V4 regions of the 16S rRNA gene. Results: The relative abundance of the three dominant bacterial phyla (Bacteroidota, Firmicutes, an","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2026-06-20T03:22:56.638Z","creation":"2025-04-20T03:35:19.991Z"},"accession":"S-EPMC9739995","cross_references":{"pubmed":["36498624"],"doi":["10.3390/jcm11237050"]}}